Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma

Investigational New Drugs

Volumn 29, Issue 2, 2011, Pages 380-391

  Luther, Daniel J ^a,b   Ohanyan, Vahagn ^a   Shamhart, Patricia E ^a,b   Hodnichak, Cheryl M ^a   Sisakian, Hamayak ^c   Booth, Tristan D ^d   Meszaros, J Gary ^a,b   Bishayee, Anupam ^b,e  

^a Northeastern Ohio Medical University   (United States)

^b KENT STATE UNIVERSITY   (United States)

^c YEREVAN STATE MEDICAL UNIVERSITY   (Armenia)

^d INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

^e NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

Author keywords

Cardiac function; Chemoprevention; Diethylnitrosamine; Echocardiography; Hepatocarcinogenesis; Resveratrol

Indexed keywords

DIETHYLNITROSAMINE; RESVERATROL; CARDIOTOXIN; STILBENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER REGRESSION; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEART; HEART CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE VOLUME; HISTOPATHOLOGY; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; RAT; RODENT; SYSTOLIC BLOOD PRESSURE; TRANSTHORACIC ECHOCARDIOGRAPHY; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; CHEMOPROPHYLAXIS; DISEASE MODEL; DRUG EFFECT; ECHOCARDIOGRAPHY; FEEDING BEHAVIOR; HUMAN; LIVER; LIVER CELL; LIVER TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SYSTOLE;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CARDIOTOXINS; CHEMOPREVENTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; FEEDING BEHAVIOR; FEMALE; HEART; HEPATOCYTES; HUMANS; LIVER; LIVER NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; STILBENES; SYSTOLE;

EID: 79957444978     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-009-9332-7     Document Type: Article

References (78)

1. Feitelson MA, Sun B, Tufan NLS, Liu J, Pan J, Lian Z (2002) Genetic mechanisms of hepatocarcinogenesis. Oncogene 21:2593-2604 (Pubitemid 34438112)
2. Llovet JM, Burroughs A, Buix J (2003) Hepatocellular carcinoma. Lancet 362:1907-1917 (Pubitemid 37518510)
3. El-Serag HB (2004) Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 127:S27-S34 (Pubitemid 39423367)
4. American Cancer Society (2009) Cancer facts and figures 2009. American Cancer Society, Atlanta
5. Bartsch H, Montesano R (1984) Relevance of nitrosamines to human cancer. Carcinogenesis 5:1381-1393 (Pubitemid 15218943)
6. Kensler TW, Egner PA, Wang JB, Zhu YR, Zhang BC, Lu PX et al (2004) Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterology 127:S310-S318 (Pubitemid 39423401)
7. Pang R, Tse E, Poon TP (2006) Molecular pathways in hepatocellular carcinoma. Cancer Lett 240:157-169 (Pubitemid 44093818)
8. Schütte K, Bornscein J, Malfertheiner P (2009) Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 27:80-92
9. Ribes J, Clèries R, Esteban L, Moreno V, Bosch FX (2008) The influence of alcohol consumption and hepatitis B and C infections on the risk of liver cancer in Europe. J Hepatol 49:233-242
10. Kensler TW, Quian GS, Chen JG, Groopman JD (2003) Translational strategies for cancer prevention in liver. J Natl Cancer Inst 3:321-329 (Pubitemid 37328852)
11. Okuno M, Kojima S, Moriwaki H (2001) Chemoprevention of hepatocellular carcinoma: concept, progress and perspectives. J Gastroenterol Hepatol 16:1329-1335 (Pubitemid 34107398)
12. Yates MS, Kensler TW (2007) Keap1 eye on the target: chemoprevention of liver cancer. Acta Pharmacol Sin 28:1331-1342 (Pubitemid 47366685)
13. Lippman SM, Hong WK (2002) Cancer chemoprevention science and practice. Cancer Res 62:5119-5125
14. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington
15. Naithani R, Huma LC, Moriarty RM, McCormick DL, Mehta RG (2008) Comprehensive review of cancer chemopreventive agents evaluated in experimental carcinogenesis models and clinical trials. Curr Med Chem 15:1044-1071 (Pubitemid 352005717)
16. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP (2009) Phytochemicals as potential chemopreventive and chemotherapeutic agents in hepatocarcinogenesis. Eur J Cancer Prev 18:13-25
17. Harikumar KB, Aggarwal BB (2008) Resveratrol, a multitargeted agent for age associated chronic diseases. Cell cycle 7:1020-1037 (Pubitemid 351679835)
18. Fremont L (2000) Biological effects of resveratrol. Life Sci 66:663-673
19. Kopp P (1998) Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox'? Eur J Endocrinol 138:619-620 (Pubitemid 28313808)
20. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506 (Pubitemid 44136961)
21. Shankar S, Singh G, Srivastava RK (2007) Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12:4839-4854
22. Saiko P, Szakmary A, Jaeger W, Szekeres T (2008) Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat Res 658:68-94 (Pubitemid 351172881)
23. Shakibaei M, Harikumar KB, Aggarwal BB (2009) Resveratrol addiction: to die or not to die. Mol Nutr Food Res 53:115-128
24. Athar M, Back JH, Kopelovich L, Bickers DR, Kim AL (2009) Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch Biochem Biophys 486:95-102
25. Pirola L, Fröjdö S (2008) Resveratrol: one molecule, many targets. IUBMB Life 60:323-332
26. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y (2004) Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24:2783-2840 (Pubitemid 39409568)
27. Kundu JK, Surh Y-J (2008) Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 269:243-261
28. Bishayee A (2009) Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res 2:409-418
29. Bishayee A, Dhir N (2009) Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem-Biol Interact 179:131-144
30. Penumathsa SV, Maulik N (2009) Resveratrol: a promising agent in promoting cardioprotection against coronary heart disease. Can J Physiol Pharmacol 87:275-286
31. Ray PS, Maulik G, Cordis GA, Bertelli AA, Bertelli A, Das DK (1999) The red wine antioxidant resveratrol protects isolated rat hearts from ischemia reperfusion injury. Free Radic Biol Med 27:160-169 (Pubitemid 29353096)
32. Bradamante S, Piccinini F, Barenghi L, Bertelli AA, De Jonge R, Beemster P et al (2000) Does resveratrol induce pharmacological preconditioning? Int J Tissue React 22:1-4 (Pubitemid 30495274)
33. Hattori R, Otani H, Maulik N, Das DK (2002) Pharmacological preconditioning with resveratrol: role of nitric oxide. Am J Physiol Heart Circ Physiol 282:H1988-H1995 (Pubitemid 34663004)
34. Hung LM, Su MJ, Chen JK (2004) Resveratrol protects myocardial ischemia-reperfusion injury through both NOdependent and NO-independent mechanisms. Free Radic Biol Med 36:774-781
35. Chen CK, Pace-Asciak CR (1996) Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharmacol 27:363-366 (Pubitemid 26129194)
36. Bertelli AA, Giovannini L, Giannessi D, Migliori M, Bernini W, Fregoni M et al (1995) Antiplatelet activity of synthetic and natural resveratrol in red wine. Int J Tissue React 17:1-3
37. Das S, Das DK (2007) Anti-inflammatory responses of resveratrol. Inflamm Allergy Drug Targets 6:168-173 (Pubitemid 47455785)
38. Olson ER, Naugle JE, Zhang X, Bomser JA, Meszaros JG (2005) Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 288:H1131-H1138 (Pubitemid 40270016)
39. Das S, Fraga CG, Das DK (2006) Cardioprotective effect of resveratrol via HO-1 expression involves p38 map kinase and PI- 3-kinase signaling, but does not involve NFkappaB. Free Radic Res 40:1066-1075 (Pubitemid 44480547)
40. Dudley J, Das S, Mukherjee S, Das DK (2009) Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 20:443-452
41. Wu T (2006) Cyclooxygenase-2 in hepatocellular carcinoma. Cancer Treat Rev 32:28-44 (Pubitemid 43159775)
42. Yildirim Y, Ozyilkan O, Bilezikci B, Akcali Z, HaberalM(2008) Lack of influence of cyclooxygenase-expression in hepatocellular carcinomas on patient survival. Asian Pacific J Cancer Prev 9:295-298
43. Giannitrapani L, Ingrao S, Soresi M, Maria Florena A, La Spada E, Sandonato L et al (2009) Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma. Ann NY Acad Sci 1155:293-299
44. Hu K-Q (2002) Rationale and feasibility of chemoprevention of hepatocellular carcinoma by cyclooxygenase-2 inhibitors. J Lab Clin Med 139:234-243 (Pubitemid 34557358)
45. Koga H (2003) Hepatocelluar carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors. Cancer 98:661-667 (Pubitemid 36959260)
46. Bishayee A, Waghray A, Lotey R, Barnes KF, Darvesh AS, Bhatia D, Carroll RT (2009) Mechanisms of resveratrol-mediated chemoprevention of hepatocellular carcinogenesis: suppression of oxidative stress and inflammation. Eighth Annual International Conference on Frontiers in Cancer Prevention Research, December 6-9, 2009, Houston, TX, USA
47. Cervello M, Montalto G (2006) Cyclooxygenase in hepatocellular carcinoma. World J Gastroenterol 12:5113-5121
48. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K (2007) Cycloxygenase-2 (COX-2) in carcinogenesis and selective COX-2 inhibitors for chemoprevention in gastrointestinal cancers. J Gastrointest Cancer 38:78-82
49. Yona D, Arber N (2004) Coxibs and cancer prevention. J Cardiovasc Pharmacol 47:S76-S81 (Pubitemid 44651790)
50. Niles RM, Cook CP, Meadows GG, Fu Y-M, McLaughlin JL, Rankin GO (2006) Resveratrol is rapidly metabolized in athymic (Nu/Nu) mice and does not inhibit human melanoma xenograft tumor growth. J Nutr 136:2542-2546 (Pubitemid 44521610)
51. Bushan KM, Rao GV, Soujanya T, Rao VJ, Saha S, Samanta A (2001) Photochemical E (trans)→Z (cis) isomerization in substituted 1-naphthylacrylates. J Org Chem 66:681-688 (Pubitemid 32163060)
52. Bishayee A, Roy S, Chatterjee M (1999) Characterization of selective induction and alteration of xenobiotic biotransforming enzymes by vanadium during diethylnitrosamine-induced chemical rat liver carcinogenesis. Oncol Res 11:41-53
53. Bishayee A, Sarkar A, Chatterjee M (2000) Further evidence for chemopreventive potential of β-carotene against experimental hepatocarcinogenesis: diethylnitrosamine-initiated and phenobarbital promoted hepatocarcinogenesis is prevented more effectively by β-carotene than by retinoic acid. Nutr Cancer 37:89-98 (Pubitemid 30650672)
54. Bishayee A, Chatterjee M (1995) Inhibition of altered liver cell foci and persistent nodule growth by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in rats. Anticancer Res 15:455-462
55. Stewart HL, Williams GM, Keysser CH, Lombart LS, Montali RJ (1980) Histological typing of liver tumors of the rat. J Natl Cancer Inst 64:177-204
56. Sahn DJ, DeMaria A, Kisslo J, Weyman A (1978) Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 58:1072-1083 (Pubitemid 9091990)
57. Bishayee A, Chatterjee M (1995) Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital. Brit J Cancer 71:1214-1220
58. Chakraborty T, Chatterjee A, Rana A, Dhachinamoorthi D, Kumar PA, Chatterjee M (2007) Carcinogen-induced early molecular events and its implication in the initiation of chemical hepatocarcinogenesis in rats: chemopreventive role of vanadium on this process. Biochim Biophys Acta 1772:48-59 (Pubitemid 44960731)
59. Lee JS, Chu IS, Mikaelyan A, Calvisi DF, Heo J, Reddy JK, Thorgeirsson SS (2004) Application of comparative functional genomics to identify best-fit mouse models to study human cancer. Nat Genetics 36:1306-1311 (Pubitemid 39577940)
60. Farber E, Sarma DS (1987) Hepatocarcinogenesis: a dynamic cellular perspective. Lab Invest 56:4-22
61. Williams GM (1980) The pathogenesis of rat liver cancer caused by chemical carcinogens. Biochim Biophys Acta 605:167-189 (Pubitemid 10044077)
62. Chen T, Hwang H, Rose ME, Nines RG, Stoner GD (2006) Chemopreventive properties of black raspberries in N-nitrosomethylbenzylamine- induced rat esophageal tumorigenesis: downregulation of cyclooxygenase-2, inducible nitric oxide synthase, and c-Jun. Cancer Res 66:2853-2859
63. Di Stefano G, Fiume L, Bolondi L, Lanza M, Pariali M, Chieco P (2005) Enhanced uptake of lactosaminated human albumin by rat hepatocarcinomas: implications for an improved chemotherapy of primary liver tumours. Liver Int 25:854-860 (Pubitemid 41038667)
64. Waitzberz DL, Goncalves EL, Faintuch J, Bevilacqua LR, Rocha CL, Cdogni AM (1989) Effects of diets with different protein levels on the growth of Walker 256 carcinosarcoma in rats. Brazil J Med Biol Res 22:447-455
65. Husting SD, Kari FW (1999) The anti-carcinogenic effects of dietary restriction: mechanisms and future directions. Mutat Res 443:235-249 (Pubitemid 29327277)
66. Whitsett T, Carpenter M, Lamartiniere CA (2006) Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 5:15
67. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82:614-619 (Pubitemid 39600090)
68. Williams LD, Burdock GA, Edwards JA, Beck M, Bausch J (2009) Safety studies conducted on high-purity trans-resveratrol in experimental animals. Food Chem Toxicol 47:2170-2182
69. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B et al (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Eng J Med 343:1520-1528
70. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G et al (2004) Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 363:1751-1756 (Pubitemid 38698377)
71. Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Lenin R, Mogun H (2004) Relationship between selective cyclooxygenase- 2 inhibitors and acute myocardial infarction in older adults. Circulation 109:2068-2073 (Pubitemid 38620213)
72. Baron JA, Sandler RS, Bresalier RS, Quan H, Riddell R, Lanas A et al (2006) A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131:1674-1682 (Pubitemid 44958508)
73. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K et al (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355:873-884 (Pubitemid 44315980)
74. Burstein B, Majuy A, Clement R, Gosselin H, Poulin F, Ethier N et al (2007) Effects of resveratrol treatment on cardiac remodeling following myocardial infarction. J Pharmacol Exp Ther 323:916-23 (Pubitemid 350146054)
75. Lin JF, Lin SM, Chih CL, Nien MW, Su HH, Hu BR, Huang SS, Tsai SK (2008) Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 89:313-317
76. Juric D, Wojciechowski P, Das DK, Netticadan T (2007) Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ Physiol 292:H2138-H2143 (Pubitemid 47084592)
77. Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE et al (2008) Resveratrol inhibits cardiac hypertrophy via AMPactivated kinase and Akt. J Biol Chem 283:24194-24201
78. Tatlidede E, Sehirli O, Velioǧlu-Oǧünc A, Cetinel S, Yeǧen BC, Yarat A et al (2009) Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43:195-205